Filip Janku Selected Research

Estrogen Receptors

1/2019	Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
1/2018	Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
8/2017	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
5/2015	Multiple gene aberrations and breast cancer: lessons from super-responders.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Filip Janku Research Topics

Disease

176	Neoplasms (Cancer) 12/2023 - 08/2005
14	Melanoma (Melanoma, Malignant) 11/2023 - 08/2005
13	Breast Neoplasms (Breast Cancer) 12/2023 - 10/2004
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023 - 10/2004
12	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 03/2011
11	Neoplasm Metastasis (Metastasis) 03/2021 - 01/2011
10	Fatigue 12/2023 - 11/2016
9	Thrombocytopenia (Thrombopenia) 10/2021 - 12/2006
8	Exanthema (Rash) 12/2023 - 02/2015
8	Diarrhea 12/2023 - 12/2006
8	Disease Progression 01/2023 - 03/2014
8	Ovarian Neoplasms (Ovarian Cancer) 10/2021 - 03/2011
7	Nausea 11/2023 - 09/2015
7	Sarcoma (Soft Tissue Sarcoma) 01/2020 - 03/2012
6	Vomiting 10/2022 - 09/2015
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 11/2021 - 03/2013
6	Triple Negative Breast Neoplasms 03/2020 - 12/2014
5	Cholangiocarcinoma 01/2023 - 01/2013
5	Neutropenia 10/2021 - 12/2006
4	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2023 - 06/2017
4	Hypoxia (Hypoxemia) 01/2023 - 11/2011
4	Erdheim-Chester Disease 01/2023 - 06/2014
4	Lung Neoplasms (Lung Cancer) 01/2022 - 05/2013
4	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 01/2014
3	Endometrial Neoplasms (Endometrial Cancer) 02/2024 - 05/2014
3	Leiomyosarcoma 12/2023 - 12/2016
3	Histiocytosis 01/2023 - 11/2010
3	Hypertension (High Blood Pressure) 01/2021 - 02/2015
3	Carcinoma (Carcinomatosis) 12/2020 - 12/2013
3	Carcinogenesis 09/2017 - 01/2011
3	Prostatic Neoplasms (Prostate Cancer) 07/2015 - 03/2014
2	Hyperglycemia 12/2023 - 01/2019
2	Dermatitis 11/2023 - 01/2018
2	Non-Langerhans-Cell Histiocytosis (Histiocytosis, Non Langerhans Cell) 01/2023 - 01/2019
2	Sinus Histiocytosis (Rosai-Dorfman Disease) 01/2023 - 01/2019
2	Head and Neck Neoplasms (Head and Neck Cancer) 12/2022 - 08/2010
2	Constipation 10/2022 - 10/2020
2	Thyroid Neoplasms (Thyroid Cancer) 01/2022 - 01/2018

Drug/Important Bio-Agent (IBA)

16	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 09/2011
16	Bevacizumab (Avastin)FDA Link 01/2020 - 11/2011
13	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 01/2011
13	DNA (Deoxyribonucleic Acid)IBA 07/2021 - 01/2011
12	Everolimus FDA Link 02/2023 - 05/2014
12	Cell-Free Nucleic AcidsIBA 10/2021 - 01/2015
10	MTOR InhibitorsIBA 11/2020 - 03/2012
8	VemurafenibIBA 02/2023 - 07/2014
8	Circulating Tumor DNAIBA 01/2023 - 05/2017
8	Proteins (Proteins, Gene)FDA Link 07/2021 - 05/2015
8	temsirolimus FDA Link 01/2018 - 11/2011
7	Carboplatin (JM8)FDA LinkGeneric 02/2023 - 06/2014
7	Tyrosine Kinase InhibitorsIBA 01/2023 - 03/2013
7	selinexorIBA 04/2022 - 08/2017
6	Paclitaxel (Taxol)FDA LinkGeneric 02/2023 - 10/2004
6	Phosphotransferases (Kinase)IBA 01/2023 - 09/2011
6	CytokinesIBA 01/2023 - 05/2014
6	pembrolizumabIBA 01/2022 - 01/2020
6	Biomarkers (Surrogate Marker)IBA 11/2021 - 03/2013
6	Cetuximab (Erbitux)FDA Link 01/2020 - 01/2014
6	ErbB Receptors (EGF Receptor)IBA 01/2020 - 09/2011
5	Sorafenib (BAY 43-9006)FDA Link 02/2023 - 04/2014
5	Monoclonal AntibodiesIBA 12/2022 - 03/2014
5	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 01/2016
5	Trastuzumab (Herceptin)FDA Link 01/2021 - 10/2004
5	pazopanib FDA Link 01/2021 - 06/2015
5	Immune Checkpoint InhibitorsIBA 12/2020 - 12/2017
4	CreatinineIBA 12/2023 - 06/2015
4	CrizotinibIBA 02/2023 - 01/2018
4	ripretinibIBA 01/2023 - 01/2019
4	Vorinostat FDA Link 11/2020 - 10/2016
4	Histone Deacetylase InhibitorsIBA 11/2020 - 03/2014
4	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020 - 05/2014
4	Formaldehyde (Formol)FDA Link 01/2019 - 04/2014
4	ParaffinIBA 01/2019 - 04/2014
4	Estrogen ReceptorsIBA 01/2019 - 05/2015
4	Lenalidomide (CC 5013)FDA Link 01/2018 - 12/2013
4	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 08/2005
3	trametinibIBA 01/2023 - 02/2015
3	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 10/2004
3	Pemetrexed (MTA)FDA Link 02/2022 - 12/2006
3	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 11/2011
3	Hormones (Hormone)IBA 01/2021 - 05/2015
3	Sirolimus (Rapamycin)FDA Link 11/2020 - 08/2015
3	ivosidenibIBA 10/2020 - 01/2019
3	TOR Serine-Threonine KinasesIBA 01/2018 - 05/2014
3	Lapatinib (GW572016)FDA Link 11/2017 - 02/2015
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 07/2015 - 12/2006
2	Metformin (Glucophage)FDA LinkGeneric 12/2023 - 01/2016
2	Gemcitabine FDA Link 01/2023 - 01/2018
2	InterferonsIBA 01/2023 - 01/2010
2	AntibodiesIBA 12/2022 - 03/2020
2	Topotecan (Hycamtin)FDA LinkGeneric 04/2022 - 10/2021
2	Argininosuccinate Synthase (Argininosuccinate Synthetase)IBA 01/2022 - 01/2021
2	ADI PEG20IBA 01/2022 - 01/2021

Therapy/Procedure

110	Therapeutics 02/2023 - 10/2004
15	Immunotherapy 12/2022 - 12/2017
14	Drug Therapy (Chemotherapy) 02/2023 - 01/2014
9	Precision Medicine 03/2021 - 12/2008
4	Time-to-Treatment 10/2021 - 02/2015
3	Aftercare (After-Treatment) 01/2022 - 01/2012
2	Injections 01/2023 - 01/2021